STRATEGIC NEWS WATCH — September 16, 2026
|
Today’s top developments:
|
What to Watch
- What “radioligand equivalent” actually means — The designation is new and the available coverage does not define its regulatory basis. The FDA’s own description of the pathway and its evidentiary requirements, not the Bexlutry approval itself, will decide whether Pluvicto and the rest of the isotope-based radioligand field are now exposed to the same treatment.
- Lifonebart’s Alzheimer’s readout — The TREM2 thesis now rests entirely on the continuing Phase 2 in Alzheimer’s. Novartis argues target validation is stronger there; watch whether the trial’s design or endpoints were adjusted after Astrals, which would say more than the stated rationale does.
- The Curium-Lantheus close — Curium’s $8 billion acquisition would create a roughly $2.1 billion-revenue radiopharma business at the moment the first equivalent approval lands in the category. Watch for antitrust review and closing timing; no date has been announced.
- Delivery over targets as a neuroscience bet — Novartis paid $125 million for antibody transport across the blood-brain barrier and Lilly licensed nucleic-acid delivery into the nervous system on the same day a CNS target failed. The test is which named asset each platform is first paired with — the only way to judge them against Roche’s Brainshuttle and its peers.
- Sling’s committed capital against a 2028 readout — $123 million funds a 130-patient Phase 3 reading out in mid-2028, into a thyroid eye disease market where Tepezza and Viridian’s Lumvoa are already approved. Watch enrolment pace; recruiting against two approved options, not the money, is the binding constraint.
This brief highlights the edition’s top stories. Read the full September 16, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.